Regadenoson

American Journal of Cardiovascular Drugs

Volumn 10, Issue 1, 2010, Pages 65-71

  Garnock Jones, Karly P ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Coronary artery disease, diagnosis; Imaging agents, diagnostic use; Regadenoson, therapeutic use; Research and development

Indexed keywords

ADENOSINE; LEXISCAN; REGADENOSON; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ANGINA PECTORIS; AREA UNDER THE CURVE; ASTHMA; ATRIOVENTRICULAR BLOCK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG STRUCTURE; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; EXERCISE TEST; FLUSHING; GOLD STANDARD; HEADACHE; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE PERFUSION; HEART RATE; HEART SCINTISCANNING; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT DEPRESSION; STEADY STATE; SUPRAVENTRICULAR PREMATURE BEAT; SYSTOLIC BLOOD PRESSURE; THORAX PAIN;

ADENOSINE; ANIMALS; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; HUMANS; MYOCARDIAL PERFUSION IMAGING; PURINES; PYRAZOLES; RECEPTOR, ADENOSINE A2A;

EID: 77149147427     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/10489040-000000000-00000     Document Type: Review

References (24)

1. Cerqueira MD. Nuclear cardiology: finally a one-stop shop for diagnosis, risk stratification, andmanagement of coronary artery disease. Clin Cardiol 2006; 29 (9 Suppl. 1): I26-33
2. Iskandrian AE, Verani MS. Nuclear imaging techniques. In: Topol E, editor. Textbook of cardiovascular medicine. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 1191-1211
3. Mitka M. New stress test agents reduce adverse effects. JAMA 2008 May 14; 299 (18): 2140
4. Buhr C, Gossl M, Erbel R, et al. Regadenoson in the detection of coronary artery disease. Vasc Health Risk Manag 2008; 4 (2): 337-340
5. Patel RN, Arteaga RB, Mandawat MK, et al. Pharmacologic stress myocardial perfusion imaging. South Med J 2007 Oct; 100 (10): 1006-1014
6. US FDA. Clinical pharmacology and biopharmaceutics review for regadenoson (Lexiscan™) [NDA-22161] [online]. Available from URL: http:// www.fda.gov/cder/foi/nda/2008/022161s000-LEXISCAN-CLINPHARM& BIOPHARMR.pdf [Accessed 2008 Jul 23]
7. Gao Z, Li Z, Baker SP, et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 2001 Jul; 298 (1): 209-218
8. Lieu HD, Shryock JC, von Mering GO, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007 Jul; 14 (4): 514-520
9. Zhao G, Linke A, Xu X, et al. Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther 2003 Oct; 307 (1): 182-189
10. Dhalla AK, Xu J, KussmaulW, et al. Differential vasodilatory effects of CVT-3146, an A2A adenosine receptor agonist in various vascular beds in anesthetized dogs. J Am Coll Cardiol 2004 Mar 3; 43 (5 Suppl. A): 367A-8A
11. Gaemperli O, Schepis T, Koepfli P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008 Jan 22; 51 (3): 328-329
12. Astellas Pharma Inc. Caffeine's effect on regadenoson administration with single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) [ClinicalTrials.gov identifier NCT00826280]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials. gov [Accessed 2009 Sep 28]
13. Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007 Sep 31; 14 (5): 645-658
14. Astellas Pharma. Lexiscan (regadenoson): US prescribing information. [online]. Available from URL: http://www.astellas.us/docs/lexiscan.pdf [Accessed 2009 Mar 23]
15. Leaker BR, O'Connor B,Hansel TT, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008 May-2008 30; 15 (3): 329-336
16. Thomas GS, Tammelin BR, Schiffman GL, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008 May-2008 30; 15 (3): 319-328
17. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007 Jul; 47 (7): 825-833
18. Gordi T, Frohna P, Sun HL, et al. A population pharmacokinetic/ pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006; 45 (12): 1201-1212
19. Hendel RC, Bateman TM, Cerqueira MD, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress singlephoton emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005 Dec 6; 46 (11): 2069-2075
20. US FDA. Medical review for regadenoson (Lexiscan™) [NDA-22161] [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2008/022161s000- LEXISCAN-MEDR.pdf [Accessed 2008 Jul 23]
21. Cerqueira MD, Nguyen P, Staehr P, et al. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective adenosine A2A agonist regadenoson versus adenosine in myocardial perfusion imaging. Integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008; 1 (3): 307-316
22. Mahmarian JJ, Cerqueira MD, Iskandrian AE, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009 Aug; 2 (8): 959-968
23. Senior R, Jacobsen AN, Kinsey C, et al. Superior safety profile of regadenoson versus adenosine in patients with chronic obstructive pulmonary disease undergoing radionuclide myocardial perfusion imaging [abstract no. P4230]. Eur Heart J 2007 Sep; 28 (Abstr. Suppl.): 721
24. Reyes E, Standbridge K, Nguyen P, et al. A comparison of the safety profile and tolerability of regadenoson and adenosine for mycardial perfusion scintigraphy in older patients [abstract no. 4.13]. J Nucl Cardiol 2007 Mar-Apr; 14: S24